Ensysce Biosciences Ownership
| ENSC Stock | USD 0.43 0.16 27.12% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 8.8 M | Current Value 9.9 M | Avarage Shares Outstanding 3.3 M | Quarterly Volatility 3.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Ensysce |
Ensysce Stock Ownership Analysis
About 22.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.22. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ensysce Biosciences recorded a loss per share of 1.94. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 31st of March 2023. Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614 PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse and PF26810, an extended-release prodrug of methadone for opioid use disorder. Ensysce Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. To learn more about Ensysce Biosciences call Lynn Kirkpatrick at 858 263 4196 or check out https://www.ensysce.com.Besides selling stocks to institutional investors, Ensysce Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Ensysce Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Ensysce Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Ensysce Biosciences Quarterly Liabilities And Stockholders Equity |
|
Only 1.17% of Ensysce Biosciences are currently held by insiders. Unlike Ensysce Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Ensysce Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Ensysce Biosciences' insider trades
Ensysce Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ensysce Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ensysce Biosciences backward and forwards among themselves. Ensysce Biosciences' institutional investor refers to the entity that pools money to purchase Ensysce Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Xtx Topco Ltd | 2024-09-30 | 0.0 | Anson Funds Management Lp | 2024-09-30 | 983.5 K | Sabby Management Llc | 2024-06-30 | 314.4 K | Geode Capital Management, Llc | 2024-09-30 | 46.1 K | Citadel Advisors Llc | 2024-09-30 | 23.6 K | Renaissance Technologies Corp | 2024-09-30 | 22.4 K | Vanguard Group Inc | 2024-09-30 | 18.2 K | Virtu Financial Llc | 2024-06-30 | 11.3 K | Tower Research Capital Llc | 2024-06-30 | 8.3 K |
Ensysce Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ensysce Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ensysce Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ensysce Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ensysce Biosciences Outstanding Bonds
Ensysce Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ensysce Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ensysce bonds can be classified according to their maturity, which is the date when Ensysce Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| ENTERGY LA LLC Corp BondUS29364WBA53 | View | |
| ENTERGY LA LLC Corp BondUS29364WBB37 | View | |
| US29364WBC10 Corp BondUS29364WBC10 | View | |
| US29364WBE75 Corp BondUS29364WBE75 | View | |
| US29364WBD92 Corp BondUS29364WBD92 | View | |
| ETR 235 15 JUN 32 Corp BondUS29364WBH07 | View | |
| ETR 31 15 JUN 41 Corp BondUS29364WBJ62 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.94) | Revenue Per Share 0.274 | Quarterly Revenue Growth (0.63) | Return On Assets (1.32) | Return On Equity (4.28) |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.